JP Morgan Chase
CEMI

JP Morgan Chase’s Chembio diagnostics, Inc. CEMI Stock Holding History

JP Morgan Chase’s Portfolio CEMI Stock Details CEMI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,493
Closed -$1K – 7594
2023
Q1 		$1K Sell
1,493
-2,027
-58% -$794 ﹤0.01% 6595
2022
Q4 		$1K Buy
3,520
+126
+4% +$38 ﹤0.01% 6489
2022
Q3 		$1K Sell
3,394
-500
-13% -$341 ﹤0.01% 6413
2022
Q2 		$3K Sell
3,894
-599
-13% -$398 ﹤0.01% 6268
2022
Q1 		$4K Sell
4,493
-28,959
-87% -$27K ﹤0.01% 6369
2021
Q4 		$38K Buy
33,452
+32,037
+2,264% +$65.2K ﹤0.01% 6037
2021
Q3 		$4K Sell
1,415
-90,949
-98% -$252K ﹤0.01% 6279
2021
Q2 		$274K Sell
92,364
-2,625
-3% -$9.15K ﹤0.01% 5076
2021
Q1 		$334K Buy
94,989
+86,243
+986% +$480K ﹤0.01% 4908
2020
Q4 		$42K Buy
8,746
+1,382
+19% +$7.14K ﹤0.01% 5197
2020
Q3 		$35K Buy
7,364
+810
+12% +$3.84K ﹤0.01% 5042
2020
Q2 		$21K Buy
+6,554
New +$62.2K ﹤0.01% 5036
2019
Q2 		– Sell
-26,395
Closed -$146K – 6207
2019
Q1 		$146K Buy
26,395
+1,072
+4% +$6.96K ﹤0.01% 4750
2018
Q4 		$143K Buy
+25,323
New +$187K ﹤0.01% 4711

Other funds holding CEMI

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's CEMI Position: Q2 2023 in Review

JP Morgan Chase sold out of Chembio diagnostics, Inc. (CEMI) in Q2 2023, closing a stake of 1,493 shares — an estimated $1K sold.

JP Morgan Chase first reported a position in CEMI in Q4 2018 and held it in 14 quarters. The position peaked at $334K in Q1 2021. 1 fund tracked by Wall St. Rank holds CEMI as of Q2 2023.

  • JP Morgan Chase reported no remaining Chembio diagnostics, Inc. position as of Q2 2023 after selling out during the quarter.
  • JP Morgan Chase sold 1,493 Chembio diagnostics, Inc. shares in Q2 2023, an estimated $1K.
  • JP Morgan Chase first reported a position in Chembio diagnostics, Inc. in Q4 2018 and held it in 14 quarters.
  • JP Morgan Chase's Chembio diagnostics, Inc. position peaked at $334K in Q1 2021.
  • 1 fund tracked by Wall St. Rank held Chembio diagnostics, Inc. as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.